Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7378493 | 0.92 | NPC1 (0.48) | ITGB3ITGA2BNR1H4PPARGPPARA | |
| SCHEMBL8214435 | 0.89 | CYP3A4 (0.48) | GFERAURKARPS6KB1CYP3A4CYP2C19 | |
| SCHEMBL7156537 | 0.89 | MGLL (0.52) | AURKARPS6KB1CYP3A4CYP2C19GAA | |
| SCHEMBL10195848 | 0.88 | MAPT (0.62) | GFERCYP3A4CYP2C19GAAMAPT | |
| SCHEMBL3929633 | 0.88 | SIRT2 (0.52) | AURKARPS6KB1CYP3A4CYP2C19GAA | |
| SCHEMBL5777563 | 0.88 | AURKA (0.51) | ITGB3ITGA2BAURKARPS6KB1CYP3A4 | |
| SCHEMBL13801959 | 0.86 | CYP3A4 (0.50) | AURKARPS6KB1CYP3A4CYP2C19RAB9A | |
| SCHEMBL13623152 | 0.86 | CYP3A4 (0.50) | AURKARPS6KB1CYP3A4CYP2C19SIRT1 | |
| SCHEMBL30844047 | 0.86 | CYP3A4 (0.50) | AURKARPS6KB1CYP3A4CYP2C19SIRT1 | |
| SCHEMBL27498370 | 0.86 | CYP3A4 (0.50) | AURKARPS6KB1CYP3A4CYP2C19SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4335512-A2 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HiberCell, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11535635-B2 | — | — | 2022-12-27 | — | — | US | disclosed |
| US-20050026994-A1 | Use of 2, 4diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | FRANCE DENNIS (US) | 2005-02-03 | — | — | US | disclosed |
| EP-1173413-B1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | NOVARTIS AG (CH) | 2004-06-30 | — | — | EP | disclosed |
| CN-1148367-C | Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same | ��ѧ�о���Ӧ����ѯ��˾ | 2004-05-05 | — | — | CN | disclosed |
| CN-1351587-A | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | NOVARTIS AG (CH) | 2002-05-29 | — | — | CN | disclosed |
| EP-1173413-A1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | Novartis AG (CH) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064863-A1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | NOVARTIS AG (CH) | 2000-11-02 | — | — | WO | disclosed |
| EP-0483667-B1 | Cyclic imino derivatives, process for their preparation and drugs containing them | THOMAE GMBH DR K (DE) | 1998-02-04 | — | — | EP | disclosed |
| US-5591769-A | PYRROLIDINE DERIVATIVES; ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541343-A | ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| EP-0483667-A2 | Cyclic imino derivatives, process for their preparation and drugs containing them | Dr. Karl Thomae GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1B, PIP5K1A, PIP5K1C | ITGB3 4432/4885ITGA2B 3890/4885NR1H4 3467/4885 |
| US-20050026994-A1 | Use of 2, 4diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | PSMB3, PSMB2, PSMB1 | ITGB3 1681/4885ITGA2B 2305/4885NR1H4 1055/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | ITGB3 4755/4885ITGA2B 4707/4885NR1H4 1743/4885 |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PI4KA | ITGB3 4719/4885ITGA2B 4390/4885NR1H4 2652/4885 |
| US-11535635-B2 | — | PIP5K1A, PI4K2A, PIP5K1B | ITGB3 4799/4885ITGA2B 4599/4885NR1H4 938/4885 |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1B, PIP5K1A, PIP5K1C | ITGB3 4375/4885ITGA2B 3835/4885NR1H4 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.